Swedish nuclear medicine software developer Hermes Medical Solutions has released its new Hybrid3D selective internal radiation therapy (SIRT) software.
The software provides dose planning with technetium-99m (Tc-99m) macroaggregated albumin using resin and glass microspheres, as well as dose verification with yttrium-90 (Y-90) microspheres, as approved by the U.S. Food and Drug Administration (FDA).
Hybrid3D is designed to assist clinicians and oncologists through both planning and verification with support for vendor-neutral clinical workflows.
